Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma.

Trabodenoson is a highly selective adenosine mimetic developed to increase the natural function of the trabecular meshwork for reducing the intraocular pressure (IOP)

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The prostaglandin analog latanoprost is designed to target the secondary uveoscleral pathway.

The randomised, double-masked, dose-ranging Phase II trial enrolled around 200 patients.

The trial will evaluate the overall benefit / risk profile of the combination therapy given via binocular topical application to patients with ocular hypertension or primary open-angle glaucoma for eight weeks.

"We have completed active recruitment of glaucoma patients in our Phase II FDC trial."

Inotek president and chief executive officer David Southwell said: “We have completed active recruitment of glaucoma patients in our Phase II FDC trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“This is an important milestone as we continue to believe our FDC programme has the potential to address a larger market opportunity than monotherapy, and provide patients with a novel treatment option that includes two complementary eye pressure lowering mechanisms."

The trial will assess a combination of 6% trabodenoson and 0.005% latanoprost, 3% trabodenoson and 0.005% latanoprost, 6% trabodenoson with 0.0025% latanoprost, as well as individual doses of 0.005% latanoprost and 0.0025% latanoprost.

The trabodenoson doses were chosen to optimise IOP decrease and maintain the established tolerability and safety profile, while the selected latanoprost doses were based on efficacy and safety profiles of various doses.

It is expected that the top-line results from the Phase II FDC trial will be reported in July.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact